Lake Street analyst Brooks O’Neil maintained a Buy rating on Tandem Diabetes Care Inc (TNDM) today and set a price target of $100. The company’s shares opened today at $61.86, close to its 52-week high of $66.35.
According to TipRanks.com, O’Neil is a 3-star analyst with an average return of 2.2% and a 50.0% success rate. O’Neil covers the Healthcare sector, focusing on stocks such as Imprimis Pharmaceuticals, Alphatec Holdings, and Lemaitre Vascular.
Currently, the analyst consensus on Tandem Diabetes Care Inc is a Strong Buy with an average price target of $62.50, representing a 1.0% upside. In a report issued on February 14, Piper Jaffray also maintained a Buy rating on the stock with a $60 price target.
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes Care Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $3.69 million. In comparison, last year the company had a GAAP net loss of $11.41 million.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is neutral on the stock. Last month, John Sheridan, the EVP & COO of TNDM sold 20,788 shares for a total of $743,306.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
